My watch list  


Systematic (IUPAC) name
Acetyl-D-3-(2´-naphtyl)-alanine- D-4-chlorophenylalanine-D-3-(3´-pyridyl)- alanine-L-serine-L-tyrosine-D-citruline-L- leucine-L-arginine-L-proline-D- alanine-amide
CAS number 120287-85-6
ATC code H01CC02
PubChem  ?
DrugBank APRD00686
Chemical data
Formula  ?
Mol. mass 1431.06 g/mol
Pharmacokinetic data
Bioavailability 85%
Protein binding 86%
Metabolism  ?
Half life 62.8 hours / 3mg single dose
Excretion Liver
Therapeutic considerations
Pregnancy cat.


Legal status


Routes Subcutaneous injection

Cetrorelix acetate is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). A synthetic decapeptide, it is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, cetrorelix is used in assisted reproduction. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is administered as a daily or weekly subcutaneous injection.

Cetrorelix is marketed by Solvay Pharmaceuticals as Cetrotide.[1]


  1. ^ 2002 Solvay press release re. Cetrorelix

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cetrorelix". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE